The effect of L-carnitine in non-alcoholic fatty liver disease
Phase 3
Recruiting
- Conditions
- onalcoholic fatty liver disease.Fatty (change of) liver, not elsewhere classified
- Registration Number
- IRCT20240129060837N1
- Lead Sponsor
- Ahvaz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 102
Inclusion Criteria
AST, ALT levels above the normal range
Sonographic findings consistent with fatty liver
No history of viral hepatitis or conditions such as hemochromatosis, Wilson’s disease, autoimmune hepatitis, alpha-1 antitrypsin deficiency or chronic liver disease
Exclusion Criteria
Significant alcohol consumption (more than 10 grams per day for women and more than 20 grams per day for men)
Pregnant or breastfeeding women
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie L-carnitine's effect on liver enzymes in non-alcoholic fatty liver disease?
How does L-carnitine compare to standard-of-care treatments like vitamin E or pioglitazone in reducing liver fat content?
Which biomarkers correlate with improved outcomes in L-carnitine therapy for non-alcoholic fatty liver disease?
What adverse events are associated with L-carnitine supplementation in NAFLD patients and how are they managed?
Are there synergistic effects when combining L-carnitine with other metabolic agents like metformin in NAFLD treatment?